Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Primary Myelofibrosis 2Thrombocythemia, Essential 1Polycythemia Vera 1Neuroblastoma 1Leukemia 1

Interventions

Cyclophosphamide 57fludarabine phosphate 48Tacrolimus 39Peripheral Blood Stem Cell Transplantation 37Busulfan 36Mycophenolic Acid 34Whole-Body Irradiation 31Antilymphocyte Serum 28Methotrexate 26Cyclosporine 25fludarabine 23Melphalan 18Filgrastim 15Radiotherapy 14thymoglobulin 12ruxolitinib 12Methylprednisolone 12Cord Blood Stem Cell Transplantation 12Stem Cell Transplantation 11Sirolimus 11Psychiatric Rehabilitation 9Flow Cytometry 9Etoposide 9Specimen Handling 7Granulocyte Colony-Stimulating Factor 7merphos 6Therapeutics 6Decitabine 6Cyclosporins 6Azacitidine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Primary Myelofibrosis × lestaurtinib × Clear all
NCT00668421 2014-11-26

CEP-701 (Lestaurtinib) in Myelofibrosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Unknown
60 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00494585 2012-06-25

CEP-701 for PH-negative Myelofibrosis

M.D. Anderson Cancer Center

Phase 2 Completed
27 enrolled 5 charts
MyeloidOther hematologic neoplasm

Leukemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡